Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract ...
Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback